This prospective, multi-center, randomized, parallel-controlled clinical trial was designed to evaluate the efficacy and safety of Lyoplant Onlay in repairing cerebral dura mater. DURAFORM was regarded as the control group. a total of 80 patients were randomized into experimental and control group (1:1).Data were collected on complications resulting in CSF leaks, surgical site infections, instrument performance parameterized other neurological complications within 30 days. Surgeons also provided data on the ease of use of the dural sealing techniques, as well as preparation and application times. The above-mentioned date were used to evaluate the efficacy and safety of Lyoplant Onlay .

Inclusion Criteria:

• Any patient between the ages of 18 and 75 years scheduled for elective cranial surgery involving a dural incision.
• Dural defects and surgical incision was classifed as level 1

Exclusion Criteria:

• local or systemic infection.
• patients with known allergy to Equipment components
• a history of traumatic head injury
• a compromised immune system or autoimmune disease
• patients who should not participate based on the surgeon's opinion
• patients participating in any other drug or device trial.
• expected survival time <12 months
• underwent chemoradiotherapy 3 months before randomization
• uncontrolled diabetes and malignant tumor
• women who were pregnant, lactating, or wished to become pregnant during the study;

The committee will debate whether to share IPD depending on the circumstances. Because some patients are unwilling to make their condition known.